TY - CHAP M1 - Book, Section TI - Metabolism of Purine & Pyrimidine Nucleotides A1 - Rodwell, Victor W. A2 - Rodwell, Victor W. A2 - Bender, David A. A2 - Botham, Kathleen M. A2 - Kennelly, Peter J. A2 - Weil, P. Anthony PY - 2018 T2 - Harper's Illustrated Biochemistry, 31e AB - OBJECTIVESAfter studying this chapter, you should be able to:Compare and contrast the roles of dietary nucleic acids and of de novo biosynthesis in the production of purines and pyrimidines destined for polynucleotide biosynthesis.Explain why antifolate drugs and analogs of the amino acid glutamine inhibit purine biosynthesis.Outline the sequence of reactions that convert inosine monophosphate (IMP), first to AMP and GMP, and subsequently to their corresponding nucleoside triphosphates.Describe the formation from ribonucleotides of deoxyribonucleotides (dNTPs).Indicate the regulatory role of phosphoribosyl pyrophosphate (PRPP) in hepatic purine biosynthesis and the specific reaction of hepatic purine biosynthesis that is feedback inhibited by AMP and GMP.State the relevance of coordinated control of purine and pyrimidine nucleotide biosynthesis.Identify the reactions discussed that are inhibited by anticancer drugs.Write the structure of the end product of purine catabolism. Comment on its solubility and indicate its role in gout, Lesch-Nyhan syndrome, and von Gierke disease.Identify reactions whose impairment leads to modified pathologic signs and symptoms.Indicate why there are few clinically significant disorders of pyrimidine catabolism. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accessmedicine.mhmedical.com/content.aspx?aid=1160190604 ER -